The xT CDx is an advanced FDA-approved assay designed for tumor and normal DNA sequencing. Incorporating a comprehensive 648-gene panel, this assay provides critical insights for diagnosing and treating solid tumors, with specific functions in guiding targeted therapies in colorectal cancer patients. The test includes a thorough mutation profiling system that allows healthcare professionals to analyze substitutions, insertions, and deletions, delivering a powerful means to refine treatment options.
Beyond the standard, the xT CDx offers tumor and normal matched sequencing to distinguish somatic alterations, reducing false-positive results and improving accuracy in clinical assessments. Its integration into clinical practices is supported by its compatibility with various companion diagnostic claims, making it an essential tool for aligning treatment decisions with approved therapeutic products. By utilizing next-generation sequencing technologies, the xT CDx supports the optimization of treatment pathways and enhances patient care through detailed molecular insights.
With the capacity to perform detailed analyses on formalin-fixed paraffin-embedded tumor tissues and matched normal samples, this assay promises high specificity and sensitivity in tumor profiling. Leveraging Tempus' cutting-edge bioinformatics infrastructure, the xT CDx ensures healthcare providers can make informed decisions supported by rich genetic data, setting a transformative benchmark in precision oncology.
